Tumour biomarkers play increasingly important roles in clinical practice in oncology and in cancer research. Firstly, biomarkers can help in the early detection of cancer, enabling early intervention and potentially improving treatment options and clinical outcomes. By measuring specific molecules or genetic alterations in the body, such as proteins, DNA, or RNA, biomarkers can indicate the presence of a tumour before it becomes symptomatic or detectable by conventional tumour imaging techniques. Secondly, biomarkers aid in the diagnosis and classification of tumours. They provide additional information that complements tumour imaging results and assist in distinguishing between benign and malignant tumours. They also help in determining the specific type or subtype of cancer, which is crucial for developing personalized treatment strategies. Certain biomarkers are associated with prognosis, providing valuable information about the likely course of the disease. They can help estimate the aggressiveness of the tumour, the likelihood of recurrence, and the overall survival rate. This knowledge assists oncologists in tailoring treatment plans and advising patients about their disease prognosis. Thirdly, biomarkers help guide treatment decisions by identifying molecular targets (or genetic alterations) that can be targeted by specific therapies. For example, the presence of certain biomarkers may indicate a higher likelihood of response to a particular drug or treatment approach. This personalized medicine approach helps optimize treatment efficacy and minimize unnecessary side effects. Fourthly, biomarkers are increasingly used to monitor a patient's response to treatment. Changes in biomarker levels over time can indicate whether the treatment is effective or ineffective, allowing for modifications or adjustments in therapy. This helps oncologists assess treatment effectiveness and make informed decisions about continuing or altering the treatment plan or clinical trial. Finally, tumour biomarkers are important in clinical research and drug development. They can be used for patient stratification by identifying appropriate patient subpopulations for clinical trials, help assess the effectiveness of new therapies, and identify potential side effects or toxicities associated with treatments. Biomarkers also aid in the development of novel drugs by serving as targets themselves for drug discovery and validation. Some of the most common biomarkers are amenable to detection with antibodies. Some examples include: 1) carcinoembryonic antigen (CEA), elevated levels of which are found in several types of cancers, including colorectal, lung, breast, pancreatic, and ovarian cancers; 2) Prostate-specific antigen (PSA), which is commonly used as a biomarker for prostate cancer; 3) CA-125, a biomarker often used for ovarian cancer; 4) HER2/neu, a biomarker used in breast cancer. Elevated HER2 levels indicate an aggressive form of breast cancer, and targeted therapies like Herceptin are used to treat HER2-positive breast cancer; 5) EGFR (Epidermal Growth Factor Receptor), a biomarker in several cancers, including lung cancer. EGFR mutations or overexpression can indicate eligibility for targeted therapies such as EGFR inhibitors. We provide a large product range of research tools for investigating tumor biomarkers, including EGFR antibodies, ErbB 2 antibodies, Vimentin antibodies, EGFR ELISA Kits, and Osteopontin ELISA Kits. Explore our full tumor biomarkers product range below and discover more, for less. Alternatively, you can explore our Tumor Antigens, Enzymes, and Oncoproteins product ranges.